HUTCHMED (China) Limited (HK:0013) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) Limited is set to receive its first commercial milestone payment of $20 million from partner Takeda, following over $200 million in sales of FRUZAQLA® for metastatic colorectal cancer. This milestone highlights the success of their global partnership strategy and strengthens HUTCHMED’s financial position as they aim to expand the drug’s indications. Fruquintinib, marketed under the FRUZAQLA® brand, has gained approvals in multiple international markets, reflecting its potential in addressing unmet needs in cancer treatment.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.